Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | GALK1 | P51570 | 8/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022003 | 0.76 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL8217786 | 0.75 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL8154846 | 0.72 | ADRA2A (0.60) | SMN1; SMN2ALDH1A1NPSR1GAATDP1 | |
| SCHEMBL21162648 | 0.70 | TP53 (0.53) | RAB9ANPC1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL2658434 | 0.70 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL14029256 | 0.70 | RAB9A (0.47) | RAB9ANPC1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL14823875 | 0.69 | GALK1 (1.00) | SMN1; SMN2ALDH1A1NPSR1GALK1TDP1 | |
| SCHEMBL10639656 | 0.68 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL880253 | 0.67 | TDP1 (0.45) | RAB9ANPC1SMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL9911667 | 0.67 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289022-A1 | TETRAMERIC ALPHA-SYNUCLEIN AND USE THEREOF | BRANDEIS UNIVERSITY (US) | 2013-10-31 | — | — | US | disclosed |
| US-8450368-B2 | Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450368-B2 | Heme oxygenase inhibitors, screening methods for heme oxygenase inhibitors and methods of use of heme oxygenase inhibitors for antimicrobial therapy | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2013-05-28 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2433634-A2 | Compounds, compositions and methods of inhibiting a-synuclein toxicity | The Whitehead Institute for Biomedical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-04-01 | — | — | US | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | SNCA, PARK7, HTT | RAB9A 912/4885NPC1 2064/4885SMN1; SMN2 41/4885 |
| US-20100081661-A1 | HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY | HMOX1, HMOX2, PPOX | RAB9A 4546/4885NPC1 3013/4885SMN1; SMN2 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.